EGFR and Wilms tumor: In addition, MYLK-AS1 has been found to promote the growth and invasion of hepatocellular carcinoma cells through EGFR/HER2-ERK1/2 signal pathway (39), At the same time, it can also target miR-424-5p/E2F7 axis, activate VEGFR-2 signal pathway, and promote tumor progression and angiogenesis (39), And promote the invasion of nephroblastoma (40).